CD5-specific TCR-T cells for treatment of relapsed or refractory T cell neoplasms

SUMMARY

Patients with T-Non Hodgkin lymphomas (T-NHL) and T-acute lymphoblastic leukemia (T-ALL) have a poor prognosis, limited therapies are available and only about 30% are cured by front-line therapy. This project seeks to complete the preclinical characterization of a novel adoptive cell therapy with a T cell receptor (TCR) against an HLA-A2 restricted epitope of the T cell antigen CD5. CD5-specific TCR-T could hence represent a novel salvage / bridging therapy option for HLA-A2+ relapsed or refractory T cell neoplasms or could be used as consolidation treatment after HLA-A2 mismatch allogeneic hematopoetic stem cell transplantation with the goal to reach long-term remission.

PROJECT GOALS

• Complete the preclinical development of a novel ATMP
• Prepare phase I clinical trial
• Establish industry partnership

LONG-TERM GOALS

• Perform phase I clinical trial
• License to Biotech/Pharma